LRI Advocates for FDA Legislation to Accelerate New Lupus Treatments

The Lupus Research Institute and its Coalition of patient groups throughout the country sent the attached letter to key senators and congress people for inclusion of provisions in new FDA legislation that will accelerate the delivery of lifesaving and life enhancing treatments for individuals affected by autoimmune diseases of unmet need such as lupus.